Navigation Links
Acomplia Reduces Blood Sugar And Promotes Weight Loss

A six-month study named SERENADE (Study Evaluating Rimonabant Efficacy in Drug Naive Diabetic Patients) announced its findings// at the World Diabetes Congress in Cape Town. The study involved 278 patients with type 2 diabetes who were not taking any diabetic drugs.

Its major finding is : Acomplia (rimonabant) can significantly improve blood sugar levels in patients with type 2 diabetes while also helping them reduce their weight.

During the study, blood sugar levels of nearly half of the patients treated on Acomplia fell significantly-to below 7 percent -- and the patients on Acomplia lost around 15 pounds of weight when compared to 6 pounds of those on placebo.

"It is extraordinary that in this last group -- about 25 percent of the participants -- rimonabant was as efficient as several of the best anti-diabetic treatments," said Marc Cluzel, Head of International Development Scientific and Medical Affairs for Sanofi-Aventis.

About 9.4 percent on Acomplia left the trial midway due to adverse effects like dizziness, nausea, anxiety, depressed mood and headache compared to 2.1 percent on placebo.

Acomplia has already been approved as a diet pill in the European Union, Mexico and Argentina, but its release in the market has been withheld for months for reasons never disclosed by Sanofi-Aventis.
PRI
'"/>




Page: 1

Related medicine news :

1. Drug Reduces Risk of Clogged Arteries, Veins
2. Sunshine Reduces MS Risk
3. Estrogen in Food Reduces Cancer Risk
4. Dental Procedure Reduces Preterm Births
5. Vaccine Reduces antibiotic-resistant infections in Children
6. Eating Fiber Reduces The Risk Of Heart Disease
7. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest
8. Anti-tobacco Advertising Can Reduces smoking Among Teens
9. Eating Fish Reduces Heart Disease
10. Co-trimoxazole Use Reduces Childhood AIDS –Related Death
11. NSAIDS, Reduces The Risk Of Oral Cancer But Causes Heart Attacks
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... ... Usually, the impending arrival of warmer weather means the gleeful banishment of ... chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic Laser ... chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the fat ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, ... ensuring high-quality results and maintaining GMP and USP compliance. In a new webinar ... with GMP requirements " these requirements are explained. The challenge is to ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm , the mission-driven ... to a new, more expansive office space in order to accommodate its growing ... distressed office building in Wethersfield, Conn. located at 936 Silas Deane Highway and ...
(Date:3/28/2017)... ... 2017 , ... With less than 10,000 dermatologists in the United States and ... limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... online, today released its inaugural survey on the State of Acne in America. ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ongoing ... website has recently developed and published an informational resource that addresses frequently asked ... on common inquiries the site’s team of third party administrator (TPA) contributors regularly ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/28/2017)...  "US Cancer Generics Market Outlook 2022" report ... trend analysis related to the emergence and integration ... in US. The report analyzes various clinical and ... generics drugs in recent years. The introduction of ... dollars for various stake holders involved US cancer ...
(Date:3/28/2017)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... and year ended December 31, 2016. ... Orexigen, beginning with the re-acquisition of the rights to ... team at Orexigen demonstrated remarkable focus, executing on a ... our Company while rewarding us full control of our ...
Breaking Medicine Technology: